top of page

Alkermes Reports Positive Results


One of our Picks to Clicks for Q4 2016, Alkermes, announces positive topline results from its pivotal phase 3 study FORWARD-5 of ALKS 5461 for Major Depressive Disorder. See company press release. The stock was up over 25% on Friday. However, the stock could have been up more on this potential blockbuster drug, but investors are still worried that the FDA might not be convinced without another trial.

 
 
 

Comments


bottom of page